½ðºÌÓéÀÖ³Ç

Brussels (Belgium), 20 May 2022 ¨C 20:00 (CEST) ¨C Regulated information 

In accordance with article 8:6 of the Royal Decree executing the Belgian Code of Companies and Associations, ½ðºÌÓéÀÖ³Ç announces that, following an exercise of stock options by a member of its personnel, it has disposed of ½ðºÌÓéÀÖ³Ç shares OTC in view of deliveries of these shares to the relevant member of the personnel, within the framework of the Long-Term Incentive Program of the ½ðºÌÓéÀÖ³Ç Group, as follows:

This press release is available on ½ðºÌÓéÀÖ³Ç SA/NV¡¯s website via the following link.

For further information, contact ½ðºÌÓéÀÖ³Ç: 

Investor Relations
Antje Witte 
T +32 2 559 94 14
antje.witte@ucb.com

Corporate Communications
Laurent Schots 
T+32 2 559 92 64
laurent.schots@ucb.com     

About ½ðºÌÓéÀÖ³Ç
½ðºÌÓéÀÖ³Ç, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 8 600 people in nearly 40 countries, the company generated revenue of € 5.8 billion in 2021. ½ðºÌÓéÀÖ³Ç is listed on Euronext Brussels (symbol: ½ðºÌÓéÀÖ³Ç). Follow us on Twitter: @½ðºÌÓéÀÖ³Ç_news